---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-051168"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:18:49.055365+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences reports positive Phase 1 PBGENE-HBV data; first human biopsy evidence of viral gene editing

## Summary
- Phase 1 ELIMINATE-B trial: 9 patients across 0.2, 0.4, 0.8 mg/kg doses (22 total administrations); no dose-limiting toxicities observed.
- All patients showed HBsAg reductions; Cohort 3 (0.8 mg/kg) had steep early declines with cumulative effect – one patient achieved 64% decrease.
- Paired liver biopsy from Cohort 2 confirmed ARCUS-mediated indel edits in HBV DNA – first direct human evidence of viral gene editing.
- Transient infusion reactions and asymptomatic platelet fluctuations; one reversible Grade 3 AST elevation resolved within 3 days.
- Cohort 3 dosing to complete Q1 2026; next step: Part 2 expansion with optimized regimen and mandatory paired biopsies.

## SEC filing metadata
- accession: 0001628280-25-051168
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000162828025051168/0001628280-25-051168-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000162828025051168/dtil-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-051168
- JSON: https://secwatch.observer/filing/0001628280-25-051168.json
- Plain text: https://secwatch.observer/filing/0001628280-25-051168.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.